A global pharmaceutical company wants to assess the potential market opportunity for an advanced treatment designed for 2 Rheumatic conditions.
The new treatment was only introduced two years into the diagnosis, the client is uncertain whether patients will be open to switching from the standard treatment.
In-depth interviews (market research) with both patients and providers revealed that the existing treatment is deeply flawed and that patients will gain maximum benefit from the advanced drug as a first line of treatment.
Motivational Interviewing was leveraged to recognize why people choose not to engage in a behaviour and what it would take for them to initiate a behaviour change.
Armed with a deep understanding of (i) patient & provider reaction to treatment profile; (ii) hesitance and inertia to switch from the existing treatment; (iii) early adopters, we identified potential enablers and barriers to switching to a new treatment for both immunological conditions.
This is very exciting and gives us confidence as we prepare for launch.
- Director, Commercial Development